ArriVent BioPharma, Inc. (AVBP) Financial Statements
Free cash flow over the same period: -$147.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVBPArriVent BioPharma, Inc.Follow AVBP — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 79.0 | 153.4 | 144.3 | |
| Operating income | -94.3 | -177.5 | -175.9 | |
| Pre-tax income | -80.5 | -166.3 | -163.7 | |
| Net income | -80.5 | -166.3 | -163.7 | |
| Diluted EPS ($) | -2.56 | -4.32 | -3.43 | |
| Diluted shares (mn) | 31.5 | 38.5 | — |
USD millions · SEC XBRL
ArriVent BioPharma, Inc. — questions
- What is ArriVent BioPharma, Inc.'s net income?
- -$163.7M over the twelve months to 2026-06-30.
- What is ArriVent BioPharma, Inc.'s free cash flow?
- -$147.9M over the twelve months to 2026-06-30.
- What are ArriVent BioPharma, Inc.'s diluted earnings per share?
- $-3.43 over the twelve months to 2026-06-30.
Every figure on this page comes from ArriVent BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.